478 related articles for article (PubMed ID: 15130080)
1. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial.
Alves MB; Motta AC; Messina WC; Migliari DA
Quintessence Int; 2004 May; 35(5):392-6. PubMed ID: 15130080
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
Rhodus NL; Bereuter J
J Otolaryngol; 2000 Feb; 29(1):28-34. PubMed ID: 10709169
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia.
Regelink G; Vissink A; Reintsema H; Nauta JM
Quintessence Int; 1998 Jun; 29(6):383-8. PubMed ID: 9728149
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study.
Alpöz E; Güneri P; Onder G; Cankaya H; Kabasakal Y; Köse T
Clin Oral Investig; 2008 Jun; 12(2):165-72. PubMed ID: 18000691
[TBL] [Abstract][Full Text] [Related]
7. Association between salivary flow rates, oral symptoms, and oral mucosal status.
Kaplan I; Zuk-Paz L; Wolff A
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Aug; 106(2):235-41. PubMed ID: 18417382
[TBL] [Abstract][Full Text] [Related]
8. Oral manifestations in patients with Sjögren's syndrome.
Soto-Rojas AE; Villa AR; Sifuentes-Osornio J; Alarcón-Segovia D; Kraus A
J Rheumatol; 1998 May; 25(5):906-10. PubMed ID: 9598889
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
10. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study.
Cankaya H; Alpöz E; Karabulut G; Güneri P; Boyacioglu H; Kabasakal Y
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul; 110(1):62-7. PubMed ID: 20610299
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of oral balance gel for dry mouth in preoperative patients].
Morita Y; Senami M; Maruya H; Urushibara T; Yasuda M
Masui; 2004 Jul; 53(7):772-6. PubMed ID: 15298244
[TBL] [Abstract][Full Text] [Related]
12. Patient selection criteria for electrostimulation of salivary production in the treatment of xerostomia secondary to Sjogren's syndrome.
Erlichman M
Health Technol Assess Rep; 1990; (8):1-7. PubMed ID: 1369638
[TBL] [Abstract][Full Text] [Related]
13. Effect of xerostomic medications on stimulated salivary flow rate in patients with Sjögren's syndrome.
Simmons DD; Al-Hashimi I; Haghighat N
Quintessence Int; 2000 Mar; 31(3):196-200. PubMed ID: 11203926
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the clinical efficacy of Biotène Oral Balance in patients with secondary Sjögren's syndrome: a pilot study.
Aliko A; Alushi A; Tafaj A; Isufi R
Rheumatol Int; 2012 Sep; 32(9):2877-81. PubMed ID: 21898068
[TBL] [Abstract][Full Text] [Related]
15. Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology.
Cho MA; Ko JY; Kim YK; Kho HS
J Oral Rehabil; 2010 Mar; 37(3):185-93. PubMed ID: 20002531
[TBL] [Abstract][Full Text] [Related]
16. Optimizing dry mouth treatment for individuals with Sjögren's syndrome.
Wu AJ
Rheum Dis Clin North Am; 2008 Nov; 34(4):1001-10, x. PubMed ID: 18984418
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren's syndrome.
Márton K; Boros I; Varga G; Zelles T; Fejérdy P; Zeher M; Nagy G
Oral Dis; 2006 Sep; 12(5):480-6. PubMed ID: 16910919
[TBL] [Abstract][Full Text] [Related]
18. Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome?
Pers JO; d'Arbonneau F; Devauchelle-Pensec V; Saraux A; Pennec YL; Youinou P
Arthritis Rheum; 2005 Aug; 52(8):2411-4. PubMed ID: 16052575
[TBL] [Abstract][Full Text] [Related]
19. Pilocarpine treatment in a mixed cohort of xerostomic patients.
Aframian DJ; Helcer M; Livni D; Robinson SD; Markitziu A; Nadler C
Oral Dis; 2007 Jan; 13(1):88-92. PubMed ID: 17241436
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new oral lubricant solution in the management of psychotropic drug-induced xerostomia: a randomized controlled trial.
Mouly SJ; Orler JB; Tillet Y; Coudert AC; Oberli F; Preshaw P; Bergmann JF
J Clin Psychopharmacol; 2007 Oct; 27(5):437-43. PubMed ID: 17873673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
